Changes in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point, expressed as GMFRs;Percentages of participants achieving greater than or equal to 2-fold and 4-fold rises from before vaccination in SARS-CoV-2 serum neutralizing antibody levels;Percentages of participants reporting adverse events;Percentages of participants reporting medically attended adverse events;Percentages of participants reporting new onset of chronic disease;Percentages of participants reporting serious adverse events;Percentages of participants reporting solicited local adverse events;Percentages of participants reporting solicited systemic adverse events;Percentages of participants with abnormal chemistry and hematology values;SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs

Changes in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point, expressed as GMFRs;Percentages of participants achieving greater than or equal to 2-fold and 4-fold rises from before vaccination in SARS-CoV-2 serum neutralizing antibody levels;Percentages of participants reporting adverse events;Percentages of participants reporting medically attended adverse events;Percentages of participants reporting new onset of chronic disease;Percentages of participants reporting serious adverse events;Percentages of participants reporting solicited local adverse events;Percentages of participants reporting solicited systemic adverse events;Percentages of participants with abnormal chemistry and hematology values;SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs